|

AMXT 1501 Dicaprate Clinical Trials

2 actively recruiting trials across 2 locations

Also known as: AMXT 1501

Pipeline

Phase 1/2: 2

Top Sponsors

  • Milton S. Hershey Medical Center1
  • Aminex Therapeutics, Inc.1

Indications

  • Cancer2
  • HER2-low Hormone Receptor Positive Breast Cancer1
  • Embryonal Tumor With Multilayered Rosettes1
  • Atypical Teratoid/Rhabdoid Tumor1
  • Melanoma (Skin Cancer)1

Little Rock, Arkansas1 trial

Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas

Arkansas Children's Hospital

Phase 1/2

Los Angeles, California1 trial

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

START Los Angeles

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.